Clearside Biomedical (id:6899 CLSD)
1.08 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:30:45 AM)
Exchange closed, opens in 1 day 8 hours
4.85 USD (4.85%)
8.00 USD (8.00%)
-4.42 USD (-4.42%)
-18.80 USD (-18.80%)
5.88 USD (5.88%)
-7.69 USD (-7.69%)
-86.50 USD (-86.50%)
About Clearside Biomedical
Market Capitalization 80.73M
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
| Headquarters (address) |
900 North Point Parkway Alpharetta 30005 GA United States |
| Phone | 678 270 3631 |
| Website | https://clearsidebio.com |
| Employees | 30 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CLSD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.920 - 2.12 |
| Market Capitalization | 80.73M |
| P/E trailing | -2.01 |
| P/E forward | -2.16 |
| Price/Sale | 10.73 |
| Price/Book | -2.81 |
| Beta | 2.33 |
| EPS | -0.500 |
| EPS United States (ID:6, base:3403) | 24.22 |